These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 25183962)

  • 1. Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects.
    Singh OP; Sundar S
    Front Immunol; 2014; 5():296. PubMed ID: 25183962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy and immunochemotherapy in combating visceral leishmaniasis.
    Yadagiri G; Singh A; Arora K; Mudavath SL
    Front Med (Lausanne); 2023; 10():1096458. PubMed ID: 37265481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Host resistance to visceral leishmaniasis: prevalence and prevention.
    Maran N; Gomes PS; Freire-de-Lima L; Freitas EO; Freire-de-Lima CG; Morrot A
    Expert Rev Anti Infect Ther; 2016; 14(4):435-42. PubMed ID: 26934623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative evaluation of efficacy of chemotherapy, immunotherapy and immunochemotherapy in visceral leishmaniasis-an experimental study.
    Joshi J; Malla N; Kaur S
    Parasitol Int; 2014 Aug; 63(4):612-20. PubMed ID: 24747611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.
    Dayakar A; Chandrasekaran S; Kuchipudi SV; Kalangi SK
    Front Immunol; 2019; 10():670. PubMed ID: 31024534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-10 receptor blockade controls the in vitro infectivity of Leishmania infantum and promotes a Th1 activation in PBMC of dogs with visceral leishmaniasis.
    de Oliveira Cardoso JM; de Brito RCF; Costa AFP; Siqueira Mathias FA; Soares Reis LE; Vieira JFP; de Oliveira Aguiar Soares RD; Reis AB; Roatt BM
    Mol Immunol; 2021 Sep; 137():20-27. PubMed ID: 34182228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history.
    Reimão JQ; Pita Pedro DP; Coelho AC
    Expert Opin Drug Discov; 2020 Jun; 15(6):647-658. PubMed ID: 32202449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Overview of Immunotherapeutic Approaches Against Canine Visceral Leishmaniasis: What Has Been Tested on Dogs and a New Perspective on Improving Treatment Efficacy.
    Gonçalves AAM; Leite JC; Resende LA; Mariano RMDS; Silveira P; Melo-Júnior OAO; Ribeiro HS; de Oliveira DS; Soares DF; Santos TAP; Marques AF; Galdino AS; Martins-Filho OA; Dutra WO; da Silveira-Lemos D; Giunchetti RC
    Front Cell Infect Microbiol; 2019; 9():427. PubMed ID: 31921703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leishmania donovani: impairment of the cellular immune response against recombinant ornithine decarboxylase protein as a possible evasion strategy of Leishmania in visceral leishmaniasis.
    Yadav A; Amit A; Chaudhary R; Chandel AS; Mahantesh V; Suman SS; Singh SK; Dikhit MR; Ali V; Rabidas V; Pandey K; Kumar A; Das P; Bimal S
    Int J Parasitol; 2015 Jan; 45(1):33-42. PubMed ID: 25449949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease.
    Roatt BM; Aguiar-Soares RD; Coura-Vital W; Ker HG; Moreira Nd; Vitoriano-Souza J; Giunchetti RC; Carneiro CM; Reis AB
    Front Immunol; 2014; 5():272. PubMed ID: 24982655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Multiplexed Assay for Detection of
    Abeijon C; Alves F; Monnerat S; Wasunna M; Mbui J; Viana AG; Bueno LL; Siqueira WF; Carvalho SG; Agrawal N; Fujiwara R; Sundar S; Campos-Neto A
    J Clin Microbiol; 2019 May; 57(5):. PubMed ID: 30787142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine Development Against Leishmania donovani.
    Das A; Ali N
    Front Immunol; 2012; 3():99. PubMed ID: 22615707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Contribution of Immune Evasive Mechanisms to Parasite Persistence in Visceral Leishmaniasis.
    de Freitas EO; Leoratti FM; Freire-de-Lima CG; Morrot A; Feijó DF
    Front Immunol; 2016; 7():153. PubMed ID: 27148272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunology of post-kala-azar dermal leishmaniasis (PKDL).
    Zijlstra EE
    Parasit Vectors; 2016 Aug; 9(1):464. PubMed ID: 27553063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunity to visceral leishmaniasis: implications for immunotherapy.
    Khadem F; Uzonna JE
    Future Microbiol; 2014; 9(7):901-15. PubMed ID: 25156379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis.
    Selvapandiyan A; Dey R; Gannavaram S; Solanki S; Salotra P; Nakhasi HL
    Vaccine; 2014 Jun; 32(31):3895-901. PubMed ID: 24837513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically modified live attenuated vaccine: A potential strategy to combat visceral leishmaniasis.
    Pandey SC; Kumar A; Samant M
    Parasite Immunol; 2020 Sep; 42(9):e12732. PubMed ID: 32418227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
    Choudhury R; Das P; De T; Chakraborti T
    Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptome Analysis Identifies Immune Markers Related to Visceral Leishmaniasis Establishment in the Experimental Model of BALB/c Mice.
    Agallou M; Athanasiou E; Kammona O; Tastsoglou S; Hatzigeorgiou AG; Kiparissides C; Karagouni E
    Front Immunol; 2019; 10():2749. PubMed ID: 31849951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Leishmania donovani disulfide isomerase as a potential target of cellular immunity against visceral leishmaniasis.
    Amit A; Chaudhary R; Yadav A; Suman SS; Narayan S; Das VN; Pandey K; Singh SK; Singh BK; Ali V; Das P; Bimal S
    Cell Immunol; 2014; 289(1-2):76-85. PubMed ID: 24732062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.